Eli Lilly and Company (NYSE:LLY) Shares Sold by SlateStone Wealth LLC

SlateStone Wealth LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,133 shares of the company’s stock after selling 35 shares during the quarter. SlateStone Wealth LLC’s holdings in Eli Lilly and Company were worth $1,826,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Lipe & Dalton bought a new position in Eli Lilly and Company during the 4th quarter worth $26,000. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company in the third quarter worth $27,000. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company in the third quarter worth $35,000. Optiver Holding B.V. bought a new position in shares of Eli Lilly and Company in the third quarter worth $36,000. Finally, Family CFO Inc bought a new position in shares of Eli Lilly and Company in the third quarter worth $40,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Down 0.8 %

Shares of NYSE LLY traded down $6.13 during mid-day trading on Wednesday, reaching $739.56. 260,664 shares of the company traded hands, compared to its average volume of 3,015,443. The stock has a market cap of $702.70 billion, a PE ratio of 128.56, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. The company’s fifty day moving average is $763.89 and its two-hundred day moving average is $664.05. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a fifty-two week low of $370.68 and a fifty-two week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.09 EPS. On average, analysts expect that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. The Goldman Sachs Group upped their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research note on Wednesday, February 21st. Finally, Morgan Stanley increased their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.